FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.
NCT03718923
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
FOXP1, also known as Forkhead-box Protein P1, is a transcription factor protein belonging to the FOX gene family. Disruptions in the FOXP1 gene cause a phenotype characterized by global developmental delay, speech deficits, mild dysmorphic features, and traits of autism spectrum disorder. This study seeks to characterize FOXP1-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- FOXP1
- Mental Retardation With Language Impairment and With or Without Autistic Features
- Autism Spectrum Disorder
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 2 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- The Seaver Autism Center for Research and Treatment · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.